Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short-term Investments (2016 - 2019)

Historic Short-term Investments for Akebia Therapeutics (AKBA) over the last 4 years, with Q4 2019 value amounting to $245000.0.

  • Akebia Therapeutics' Short-term Investments fell 9984.53% to $245000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $245000.0, marking a year-over-year decrease of 9984.53%. This contributed to the annual value of $245000.0 for FY2019, which is 9984.53% down from last year.
  • As of Q4 2019, Akebia Therapeutics' Short-term Investments stood at $245000.0, which was down 9984.53% from $22.7 million recorded in Q3 2019.
  • In the past 5 years, Akebia Therapeutics' Short-term Investments registered a high of $240.1 million during Q3 2017, and its lowest value of $245000.0 during Q4 2019.
  • Moreover, its 4-year median value for Short-term Investments was $161.4 million (2017), whereas its average is $143.6 million.
  • In the last 5 years, Akebia Therapeutics' Short-term Investments surged by 15144.1% in 2017 and then plummeted by 9984.53% in 2019.
  • Quarter analysis of 4 years shows Akebia Therapeutics' Short-term Investments stood at $73.0 million in 2016, then skyrocketed by 139.43% to $174.8 million in 2017, then dropped by 9.43% to $158.3 million in 2018, then plummeted by 99.85% to $245000.0 in 2019.
  • Its Short-term Investments was $245000.0 in Q4 2019, compared to $22.7 million in Q3 2019 and $49.6 million in Q2 2019.